SCNI CEO Amir Reichman Acquires 400 Million Shares in Insider Buy
SCNI's CEO Amir Reichman made a significant insider purchase of 400 million shares on June 16, 2026.
Key Points
- SCNI CEO Amir Reichman bought 400 million shares on June 16, 2026, showing substantial insider confidence.
- SCNI shares traded at approximately $0.32, with insider buying potentially influencing market perception.
- Institutional peers like XTX Topco Ltd and UBS Group AG reduced their SCNI holdings, while others maintained their positions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Amir Reichman, the Chief Executive Officer of SCNI, made a notable insider purchase on June 16, 2026, acquiring 400 million shares of the company. This move, not part of a pre-planned trading program, may signal confidence in SCNI's future prospects. The transaction did not specify a purchase price or total value.
Insider Buying and Selling at Scinai Immunotherapeutics Ltd.
On June 16, 2026, SCNI's CEO, Amir Reichman, bought 400 million shares in an unplanned transaction, reinforcing his commitment to the company. Additionally, Mark Germain, also made an insider purchase, acquiring 120 million shares on the same day.
Other Institutional Activity in SCNI
While Amir Reichman increased his stake, several institutional investors adjusted their positions in SCNI. XTX Topco Ltd reduced its holdings by 3,253 shares, ending with 24,041 shares valued at approximately $13,283. UBS Group AG also cut its position by 829 shares, holding 919 shares worth about $524. Northwestern Mutual Wealth Management Co and Citadel Advisors LLC exited their positions entirely, selling all their shares.
Scinai Immunotherapeutics Ltd. Stock Down 87.1%
Shares of SCNI traded around $0.32, reflecting the market's valuation of the company. The recent insider buying activity might influence investor sentiment and potentially impact the stock's performance.
Bottom Line
Amir Reichman's significant insider purchase of 400 million shares in SCNI on June 16, 2026, highlights a strong vote of confidence from the company's leadership. While some institutional investors reduced or exited their positions, this insider activity could be a positive signal for the market. As always, it's important to remember that insider transactions are reported after the fact and may not indicate future stock performance.
Get Scinai Immunotherapeutics Ltd. alerts
New 13F filings, insider trades, and analyst moves on $SCNI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.